KR850000241A - 경구용 당뇨병 치료제 제형의 제조방법 - Google Patents
경구용 당뇨병 치료제 제형의 제조방법 Download PDFInfo
- Publication number
- KR850000241A KR850000241A KR1019840003189A KR840003189A KR850000241A KR 850000241 A KR850000241 A KR 850000241A KR 1019840003189 A KR1019840003189 A KR 1019840003189A KR 840003189 A KR840003189 A KR 840003189A KR 850000241 A KR850000241 A KR 850000241A
- Authority
- KR
- South Korea
- Prior art keywords
- basic
- active substance
- mixture
- excipient
- excipients
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 13
- 238000009472 formulation Methods 0.000 title claims 3
- 238000002360 preparation method Methods 0.000 title claims 3
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 14
- 238000000034 method Methods 0.000 claims 13
- 239000013543 active substance Substances 0.000 claims 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 6
- 239000000463 material Substances 0.000 claims 6
- -1 octamethylene imino group Chemical group 0.000 claims 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 4
- 239000002202 Polyethylene glycol Substances 0.000 claims 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 4
- 229920001223 polyethylene glycol Polymers 0.000 claims 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 4
- 239000002904 solvent Substances 0.000 claims 4
- 230000002378 acidificating effect Effects 0.000 claims 3
- 229940127017 oral antidiabetic Drugs 0.000 claims 3
- 229920000642 polymer Polymers 0.000 claims 3
- 239000005711 Benzoic acid Substances 0.000 claims 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims 2
- 235000019766 L-Lysine Nutrition 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 2
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims 2
- 229920002472 Starch Polymers 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 2
- UWFFNDSXSPUNTR-UHFFFAOYSA-N aluminum magnesium silicic acid trihydroxy(oxido)silane silicate Chemical compound [Mg+2].[Al+3].O[Si](O)(O)O.O[Si](O)(O)[O-].[O-][Si]([O-])([O-])[O-] UWFFNDSXSPUNTR-UHFFFAOYSA-N 0.000 claims 2
- 229910021529 ammonia Inorganic materials 0.000 claims 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims 2
- 239000001506 calcium phosphate Substances 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 235000019700 dicalcium phosphate Nutrition 0.000 claims 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims 2
- 239000003995 emulsifying agent Substances 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 150000007529 inorganic bases Chemical class 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims 2
- 150000007530 organic bases Chemical class 0.000 claims 2
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 claims 2
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims 2
- 239000000377 silicon dioxide Substances 0.000 claims 2
- 235000012239 silicon dioxide Nutrition 0.000 claims 2
- 239000011734 sodium Substances 0.000 claims 2
- 229910052708 sodium Inorganic materials 0.000 claims 2
- 239000001488 sodium phosphate Substances 0.000 claims 2
- 229910000162 sodium phosphate Inorganic materials 0.000 claims 2
- 239000000600 sorbitol Substances 0.000 claims 2
- 239000008107 starch Substances 0.000 claims 2
- 235000019698 starch Nutrition 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims 2
- 229940078499 tricalcium phosphate Drugs 0.000 claims 2
- 235000019731 tricalcium phosphate Nutrition 0.000 claims 2
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Polymers OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Polymers FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 claims 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- JNYAEWCLZODPBN-UHFFFAOYSA-N 2-(1,2-dihydroxyethyl)oxolane-3,4-diol Polymers OCC(O)C1OCC(O)C1O JNYAEWCLZODPBN-UHFFFAOYSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims 1
- 229940100389 Sulfonylurea Drugs 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000011149 active material Substances 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 230000003178 anti-diabetic effect Effects 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 150000002191 fatty alcohols Chemical class 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 229940049964 oleate Drugs 0.000 claims 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims 1
- JNYAEWCLZODPBN-CTQIIAAMSA-N sorbitan Polymers OCC(O)C1OCC(O)[C@@H]1O JNYAEWCLZODPBN-CTQIIAAMSA-N 0.000 claims 1
- 229920002554 vinyl polymer Polymers 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
- C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
- C07C405/0033—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
Abstract
내용 없음.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 건강한 지원자의 글루코스 농도 비교를 나타낸다.
제2도는 글라퀴돈의 혈장농도를 나타낸다.
Claims (13)
- 용매중 하나 이상의 용해제 및/또는 유화물질 존재하에 산성적으로 반응하는 활성물질을 염기성 부형제로 용해시키거나, 양성적으로 반응하는 활성물질을 염기성 또는 산성 부형제로 용해시키거나, 염기성적으로 반응하는 활성물질을 산성 부형제로 용해시키고, 이때 염기성 또는 산성 부형제에 대한 활성물질의 몰비는 1:1이하로 하여야 하며, 생성된 용액을 수-불용성 담체에 적용시킨 다음에 건조시키고, 이 생성물을 될 수 있는 한 부형제를 가하여 더욱 처리하여 약제학적 제형을 제조함을 특징으로 하여, 항당뇨병 활성물질을 함유하는 경구용 제제 형태를 제조하는 방법.
- 제1항에 있어서, 경구용 항당뇨병 활성 설포닐우레아가 사용됨을 특징으로 하는 방법.
- 제2항에 있어서, 글리퀴돈이 활성물질로서 사용됨을 특징으로 하는 방법.
- 제1항에 있어서, 사용된 경구용 항당뇨병 활성물질이 a) 일반식(Ⅰ)의 4-[2-아로일아미노)에틸]-벤조산, 또는 b) 일반식(Ⅱ)의 치환된 4-(아르알킬아미노카보닐메틸)-벤조산 또는 이들의 혼합물임을 특징으로 하는 방법.상기식에서 R1은 할로겐 원자, 바람직하게는 염소원자이고, R2는 탄소수 1내지 3의 알콕시그룹, 바람직하게는 메톡시그룹, 또는 피페리딘-1-일 또는 옥타메틸렌 이미노 그룹이며, R3는 탄소수 1 내지 4의 알킬그룹, 바람직하게는 n-프로필, 또는 페닐그룹이고, R4는 피레리딘-1-일, 피롤리딘-1-일 또는 헥사메틸렌이미노그룹이며, R5는 수소 또는 할로겐원자 또는 메틸 또는 메톡시그룹이다.
- 제1항 내지 제4항중의 어느 하나에 있어서, 염기성 부형제(이때, 염기성 부형제의 혼합물도 또한 사용할 수 있다)에 대한 활성물질의 몰비가 1:1.1 내지 1:10중량부로 유지됨을 특징으로 하는 방법.
- 제1항 내지 5항 중의 어느 하나에 있어서, 용해물질 총량에 대한 활성물질의 비가 1:1 내지 1:10중량부로 유지됨을 특징으로 하는 방법.
- 제1항 내지 6항 중의 어느 하나에 있어서, 사용된 수-불용성 담체가 고도로 분산된 실리콘 다이옥사이드, 미세결정성 셀룰로우즈, 염기성 알루미늄 옥사이드, 마그네슘-알루미늄-트리실리케이트, 교차 결합된 폴리비닐 피롤리돈, 나트륨 카복시메틸 전분, 트리칼슘 포스페이트, 칼슘 하이드로겐 포스페이트, 또는 이들 물질들의 혼합물이고, 사용된 용해제 및/또는 유화물질이 폴리비닐 피롤리돈, 폴리에틸렌 글리콜, 폴리에톡실화된 소르비탄모노-올레이트, 소르비톨, 폴리옥시에틸렌 폴리옥시프로필렌폴리머, 폴리옥시에틸렌 지방알코올 에테르 및 글리세롤 폴리에틸렌 글리콜옥시스테아레이트 또는 이들 물질들의 혼합물임을 특징으로 하는 방법.
- 제7항에 있어서, 폴리비닐피롤리돈 및/또는 폴리옥시에틸렌 폴리옥시프로필렌 폴리머가 용해물질로서 사용됨을 특징으로 하는 방법.
- 제1항 내지 제8항 중의 어느 하나에 있어서, 사용된 염기성 부형제가 생리적으로 무해한 무기 또는 유기 염기, 특히 수산화나트륨 용액, 수산화칼륨 용액, 암모니아, 3급-나트륨 포스페이트, 디에탄올아민, 에틸렌디아민, L-리신 또는 N-메틸글루카아민임을 특징으로 하는 방법.
- 제1항에 있어서, 활성물질 또는 활성물질들의 혼합물 이외에도, 염기성 부형제 또는 염기성 부형제의 혼합물, 하나 이상의 수-불용성 담체 및 임의로 하나 이상의 용해제 및/또는 부형제를 함유하며, 이때 염기성 부형제에 대한 활성물질의 몰비가 1:1이하임을 특징으로 하는 제제 형태의 제조방법.
- 제1항에 있어서, 함유된 염기가 생리적으로 허용되는 무기 또는 유기 염기이고, 산이 황산이며, 수-불용성 담체가 고도로 분산된 실리콘 다이옥사이드, 미세결정성 셀룰로오즈, 염기성 알루미늄 옥사이드, 마그네슘-알루미늄-트리실리케이트, 교차 결합된 폴리비닐피롤리돈, 나트륨카복시메틸 전분, 트리칼슘 포스페이트, 칼슘하이드로겐포스페이트 또는 이들 물질들의 혼합물이고, 용해물질이 폴리비닐피롤리돈, 폴리에틸렌 글리콜, 폴리에톡실화된 소르비탄모노-올레이트, 소르비톨, 폴리옥시에틸렌 폴리옥시르로필렌폴리머, 글리세롤폴리에틸렌 글리콜옥시스테아레이트 또는 이들 물질들의 혼합물임을 특징으로 하는 제제 형태의 제조방법.
- 제1항, 제10항 및 제11항 중의 어느 하나에 있어서, 염기성 부형제로서 수산화 나트륨 용액, 수산화 칼륨 용액, 암모니아, 3급-나트륨 포스페이트, 디에탈올아민, 에틸렌디아민, L-리신 또는 N-메틸글루카민을 함유하며, 이때 염기성 부형제에 대한 활성물질의 몰비가 1:1.1 내지 1:10임을 특징으로 하는 제제형태의 제조방법.
- 제1항 및 제10항 내지 제12항 중의 어느 하나에 있어서, 활성물질과 용해 부형제 또는 이들의 혼합물을 1:1 내지 1:10중량비의 비율로 함유하고, 활성물질과 담체 또는 이들의 혼합물을 1:1 내지 1:12중량부의 비율로 함유함을 특징으로 하는 제제형태의 제조방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DEP3320583.3 | 1983-06-08 | ||
| DE19833320583 DE3320583A1 (de) | 1983-06-08 | 1983-06-08 | Neue galenische zubereitungsformen von oralen antidiabetika und verfahren zu ihrer herstellung |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR850000241A true KR850000241A (ko) | 1985-02-26 |
| KR910004572B1 KR910004572B1 (ko) | 1991-07-06 |
Family
ID=6200886
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019840003189A KR910004572B1 (ko) | 1983-06-08 | 1984-06-07 | 경구용 당뇨병 치료제 제형의 제조방법 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US4708868A (ko) |
| EP (1) | EP0128482B1 (ko) |
| JP (1) | JPS6075435A (ko) |
| KR (1) | KR910004572B1 (ko) |
| AT (1) | ATE49886T1 (ko) |
| AU (1) | AU562803B2 (ko) |
| CA (1) | CA1228300A (ko) |
| DD (1) | DD223360A5 (ko) |
| DE (2) | DE3320583A1 (ko) |
| DK (1) | DK162018C (ko) |
| ES (1) | ES8601697A1 (ko) |
| FI (1) | FI85218C (ko) |
| GB (1) | GB2142235B (ko) |
| GR (1) | GR82363B (ko) |
| HK (1) | HK72287A (ko) |
| HU (1) | HU192407B (ko) |
| IE (1) | IE57792B1 (ko) |
| IL (1) | IL72033A (ko) |
| MY (1) | MY100764A (ko) |
| NO (1) | NO168629C (ko) |
| NZ (1) | NZ208416A (ko) |
| PT (1) | PT78711B (ko) |
| SG (1) | SG48087G (ko) |
| ZA (1) | ZA844295B (ko) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3320583A1 (de) * | 1983-06-08 | 1984-12-13 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue galenische zubereitungsformen von oralen antidiabetika und verfahren zu ihrer herstellung |
| US5312924A (en) | 1983-12-30 | 1994-05-17 | Dr. Karl Thomae Gmbh | Phenylacetic acid benzylamides |
| FR2577437A1 (fr) * | 1985-02-21 | 1986-08-22 | Corbiere Jerome | Nouveau procede de solubilisation des composes chimiques et les preparations aqueuses ainsi obtenues |
| DE3927882A1 (de) * | 1989-08-23 | 1991-02-28 | Bauer Kurt Heinz | Hochwirksame, schnell resorbierbare zubereitungsformen von glibenclamid, verfahren zu ihrer herstellung und ihre verwendung |
| US5258185A (en) * | 1989-08-23 | 1993-11-02 | Bauer Kurt H | Highly active, rapidly absorbable formulations of glibenclamide, processes for the production thereof and their use |
| US6361795B1 (en) | 1989-09-05 | 2002-03-26 | Alza Corporation | Method for lowering blood glucose |
| US5091190A (en) * | 1989-09-05 | 1992-02-25 | Alza Corporation | Delivery system for administration blood-glucose lowering drug |
| US5591454A (en) * | 1989-09-05 | 1997-01-07 | Alza Corporation | Method for lowering blood glucose |
| US5024843A (en) * | 1989-09-05 | 1991-06-18 | Alza Corporation | Oral hypoglycemic glipizide granulation |
| WO1992012633A1 (en) * | 1991-01-16 | 1992-08-06 | Fmc Corporation | Carrier for active agents, and solid dosage forms prepared therewith |
| US5643591A (en) * | 1991-01-16 | 1997-07-01 | Fmc Corporation | Solid dosage forms |
| DE59109240D1 (de) * | 1991-06-21 | 2002-10-10 | Boehringer Ingelheim Pharma | Verfahren zur Herstellung von (S)-3-Methyl-1-(2-piperidino-phenyl)-1-butylamin |
| US5246711A (en) * | 1992-02-27 | 1993-09-21 | Alza Corporation | Dosage form for treating dysthymia |
| US5330762A (en) * | 1992-02-27 | 1994-07-19 | Alza Corporation | Tandospiaine antidepressive therapy |
| US5246710A (en) * | 1992-02-27 | 1993-09-21 | Alza Corporation | Dosage form for treating cyclothymia |
| US5688518A (en) * | 1992-02-27 | 1997-11-18 | Alza Corporation | Antidepressive therapy |
| US5185158A (en) * | 1992-02-27 | 1993-02-09 | Alza Corporation | Dosage form comprising succinimide drug for treating depressive disorders and composition comprising same |
| US5858407A (en) * | 1992-02-27 | 1999-01-12 | Alza Corporation | Method for administering tandospirone |
| US7071298B2 (en) * | 1997-02-05 | 2006-07-04 | Fox Chase Cancer Center | Compounds and methods for treating glycogen storage disease and other pathological conditions resulting from formation of age-proteins |
| US6004958A (en) * | 1997-02-05 | 1999-12-21 | Fox Chase Cancer Center | Compounds and methods for therapeutic intervention in preventing diabetic complications and procedures for assessing a diabetic's risk of developing complications and determining the efficacy of therapeutic intervention |
| US6291495B1 (en) | 1997-02-24 | 2001-09-18 | Robert B. Rieveley | Method and composition for the treatment of diabetes |
| US6153632A (en) * | 1997-02-24 | 2000-11-28 | Rieveley; Robert B. | Method and composition for the treatment of diabetes |
| US6099859A (en) | 1998-03-20 | 2000-08-08 | Andrx Pharmaceuticals, Inc. | Controlled release oral tablet having a unitary core |
| DK1067910T3 (da) * | 1998-04-03 | 2004-10-04 | Egalet As | Komposition med styret afgivelse |
| US6099862A (en) | 1998-08-31 | 2000-08-08 | Andrx Corporation | Oral dosage form for the controlled release of a biguanide and sulfonylurea |
| US8236352B2 (en) | 1998-10-01 | 2012-08-07 | Alkermes Pharma Ireland Limited | Glipizide compositions |
| US7258869B1 (en) | 1999-02-08 | 2007-08-21 | Alza Corporation | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle |
| NZ513441A (en) † | 1999-02-08 | 2004-01-30 | Alza Corp | Stable non-aqueous single phase viscous drug delivery vehicles comprising a polymer a solvent and a surfactant |
| DK1179342T3 (da) * | 1999-05-21 | 2006-07-31 | Kissei Pharmaceutical | Medicinske sammensætninger til öjeblikkelig frigivelse ved oral anvendelse |
| DE60223382T2 (de) | 2001-06-29 | 2008-09-11 | Eurand Pharmaceuticals Ltd., Bray | Verfahren für die thermodynamische aktivierung von wasserlöslichen arzneimitteln, die in vernetzten polymeren geladen sind |
| FR2827517B1 (fr) * | 2001-07-23 | 2003-10-24 | Bioalliance Pharma | Systemes therapeutiques bioadhesifs a liberation prolongee |
| WO2003024430A1 (en) | 2001-09-21 | 2003-03-27 | Egalet A/S | Morphine polymer release system |
| US20040234602A1 (en) * | 2001-09-21 | 2004-11-25 | Gina Fischer | Polymer release system |
| WO2003024426A1 (en) * | 2001-09-21 | 2003-03-27 | Egalet A/S | Controlled release solid dispersions |
| US20030187074A1 (en) * | 2002-03-04 | 2003-10-02 | Javed Hussain | Oral compositions for treatment of diabetes |
| US20030219482A1 (en) * | 2002-03-21 | 2003-11-27 | Chaudhari Sunil Sudhakar | Multiparticulate compositions for once-a-day administration |
| SE526943C2 (sv) * | 2002-08-26 | 2005-11-22 | Indevex Ab | Födoämneskompositionsprodukt |
| US20040151772A1 (en) * | 2002-11-08 | 2004-08-05 | Egalet A/S | Controlled release carvedilol compositions |
| EP1562607A1 (en) * | 2002-11-15 | 2005-08-17 | Ranbaxy Laboratories, Ltd. | Pharmaceutical dosage forms of biguanide-sulfonylurea combinations |
| US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
| EP1610767B1 (en) * | 2003-03-26 | 2011-01-19 | Egalet A/S | Morphine controlled release system |
| ES2307003T3 (es) * | 2003-03-26 | 2008-11-16 | Egalet A/S | Composiciones matriciales para el suministro controlado de sustancias medicamentosas. |
| US20050202063A1 (en) * | 2003-08-26 | 2005-09-15 | Ebn International Kft | Food product |
| US20050053669A1 (en) * | 2003-09-05 | 2005-03-10 | Boehringer Ingelheim International Gmbh | Administration form for the oral application of poorly soluble acidic and amphorteric drugs |
| DE10341414A1 (de) * | 2003-09-05 | 2005-03-31 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Oral zu applizierende Darreichungsform für schwerlösliche saure und amphotere Wirkstoffe |
| KR100760430B1 (ko) * | 2004-12-31 | 2007-10-04 | 한미약품 주식회사 | 당뇨병 치료제의 경구 투여용 서방성 복합 제제 및 이의제조 방법 |
| US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
| WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
| CN101188999B (zh) * | 2005-06-03 | 2012-07-18 | 尹格莱特股份有限公司 | 用于递送分散在分散介质中的活性物质的药物传递系统 |
| EP1837020A1 (en) | 2006-03-24 | 2007-09-26 | Bioalliance Pharma | Mucosal bioadhesive slow release carrier for delivering active principles |
| ES2351527T3 (es) | 2006-05-30 | 2011-02-07 | Intarcia Therapeutics, Inc | Modulador de flujo en dos piezas con conducto interno para un sistema osmótico de administración. |
| NZ574524A (en) | 2006-08-09 | 2011-07-29 | Intarcia Therapeutics Inc | Piston assembly for positioning lumen of a reservoir for an osmotic delivery having a columnar body and a spring |
| US20100029721A1 (en) * | 2006-09-29 | 2010-02-04 | Novo Nordisk A/S | Pharmaceutical Formulation Comprising Metformin and Repaglinide |
| US20100291205A1 (en) * | 2007-01-16 | 2010-11-18 | Egalet A/S | Pharmaceutical compositions and methods for mitigating risk of alcohol induced dose dumping or drug abuse |
| KR101476472B1 (ko) * | 2007-03-30 | 2015-01-05 | 암브룩스, 인코포레이티드 | 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도 |
| EP2157967B1 (en) | 2007-04-23 | 2013-01-16 | Intarcia Therapeutics, Inc | Suspension formulations of insulinotropic peptides and uses thereof |
| NZ580972A (en) | 2007-06-04 | 2012-02-24 | Egalet Ltd | Controlled release pharmaceutical compositions for prolonged effect |
| WO2009102467A2 (en) | 2008-02-13 | 2009-08-20 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
| CA2751667C (en) | 2009-02-06 | 2016-12-13 | Egalet Ltd. | Immediate release composition resistant to abuse by intake of alcohol |
| EP2228066A1 (en) * | 2009-03-03 | 2010-09-15 | LEK Pharmaceuticals d.d. | Pharmaceutical compositions of sulphonylurea-based active pharmaceutical ingredient with excellent dissolution properties |
| EP2445487A2 (en) | 2009-06-24 | 2012-05-02 | Egalet Ltd. | Controlled release formulations |
| LT2462246T (lt) | 2009-09-28 | 2017-11-27 | Intarcia Therapeutics, Inc | Esminio stacionaraus vaisto tiekimo greitas įgyvendinimas ir (arba) nutraukimas |
| EP2438911A1 (en) * | 2010-10-08 | 2012-04-11 | LEK Pharmaceuticals d.d. | Pharmaceuticals compositions comprising sulphonylurea-class insulin secretagogue and polyethylene glycol castor oil |
| US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
| CA2877183A1 (en) | 2012-07-06 | 2014-01-09 | Egalet Ltd. | Abuse deterrent pharmaceutical compositions for controlled release |
| US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
| KR102637699B1 (ko) | 2014-10-24 | 2024-02-19 | 브리스톨-마이어스 스큅 컴퍼니 | 변형된 fgf-21 폴리펩티드 및 그의 용도 |
| JP6993235B2 (ja) | 2015-06-03 | 2022-01-13 | インターシア セラピューティクス，インコーポレイティド | インプラントの設置及び撤去システム |
| EP3458084B1 (en) | 2016-05-16 | 2020-04-01 | Intarcia Therapeutics, Inc | Glucagon-receptor selective polypeptides and methods of use thereof |
| USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
| USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
| KR20190104039A (ko) | 2017-01-03 | 2019-09-05 | 인타르시아 세라퓨틱스 인코포레이티드 | Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법 |
| CN115671203B (zh) * | 2022-11-24 | 2023-10-27 | 广州中医药大学科技产业园有限公司 | 一种用于降糖降脂的中药复方提取物及其提取方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3668215A (en) * | 1967-11-25 | 1972-06-06 | Bayer Ag | Aryl-sulphonyl-semicarbazides containing heterocyclic acylamino groups |
| NL138933B (nl) * | 1969-03-26 | 1973-05-15 | Erba Carlo Spa | Werkwijze voor het bereiden van benzeensulfonylureumderivaten met bloedsuikerspiegelverlagende werking. |
| US3708486A (en) * | 1969-04-17 | 1973-01-02 | Boehringer Sohn Ingelheim | 2-(p-(n'-cycloalkyl-carbamido-n-sulfonyl)-phenethyl)-1,2,3,4-tetrahydro-1,3-dioxo-4,4-dimethyl-isoquinolines and alkali metal salts thereof |
| NL7314765A (ko) * | 1972-10-31 | 1974-05-02 | ||
| DE2657382A1 (de) * | 1976-12-17 | 1978-06-29 | Thera Ges Fuer Patente | Orales antidiabetikmittel |
| JPS6026093B2 (ja) * | 1978-03-14 | 1985-06-21 | 住友製薬株式会社 | ゲフアルナート含有固型製剤の製造方法 |
| DE3013839A1 (de) * | 1979-04-13 | 1980-10-30 | Freunt Ind Co Ltd | Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung |
| ATE22530T1 (de) * | 1980-07-29 | 1986-10-15 | Sanofi Sa | Durch saeure stabilisierte mischungen von thienopyridinderivaten und verfahren zum verhindern der zersetzung solcher verbindungen. |
| EP0046961B1 (de) * | 1980-08-29 | 1985-02-13 | Byk Gulden Lomberg Chemische Fabrik GmbH | Epoxi-cycloalkylalkancarbonsäuren, Verfahren zu ihrer Herstellung, ihre Verwendung sowie sie enthaltende Arzneimittel |
| DE3100535A1 (de) * | 1981-01-10 | 1982-08-12 | Dr. Karl Thomae Gmbh, 7950 Biberach | "neue carbonsaeure-derivate, ihre herstellung und ihre verwendung als arzneimittel" |
| DE3225188A1 (de) * | 1982-07-06 | 1984-01-12 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue phenylessigsaeurederivate, ihre herstellung und diese verbindungen enthaltende arzneimittel |
| DE3124090A1 (de) * | 1981-06-19 | 1983-01-05 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue orale dipyridamolformen |
| DE3126703A1 (de) * | 1981-07-07 | 1983-01-27 | Dr. Karl Thomae Gmbh, 7950 Biberach | Bromhexin-retardform und verfahren zu ihrer herstellung |
| GB2118040A (en) * | 1982-02-15 | 1983-10-26 | Hoechst Uk Ltd | Oral anti-diabetic preparation |
| DE3320583A1 (de) * | 1983-06-08 | 1984-12-13 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue galenische zubereitungsformen von oralen antidiabetika und verfahren zu ihrer herstellung |
| DE3320582A1 (de) * | 1983-06-08 | 1984-12-13 | Dr. Karl Thomae Gmbh, 7950 Biberach | Gliquidonhaltige zubereitungsformen und verfahren zu ihrer herstellung |
-
1983
- 1983-06-08 DE DE19833320583 patent/DE3320583A1/de not_active Withdrawn
-
1984
- 1984-05-31 US US06/616,010 patent/US4708868A/en not_active Expired - Lifetime
- 1984-06-01 AT AT84106271T patent/ATE49886T1/de not_active IP Right Cessation
- 1984-06-01 DE DE8484106271T patent/DE3481170D1/de not_active Expired - Fee Related
- 1984-06-01 EP EP84106271A patent/EP0128482B1/de not_active Expired - Lifetime
- 1984-06-05 IL IL72033A patent/IL72033A/xx unknown
- 1984-06-06 DD DD84263870A patent/DD223360A5/de not_active IP Right Cessation
- 1984-06-07 IE IE1422/84A patent/IE57792B1/en not_active IP Right Cessation
- 1984-06-07 ZA ZA844295A patent/ZA844295B/xx unknown
- 1984-06-07 CA CA000456097A patent/CA1228300A/en not_active Expired
- 1984-06-07 FI FI842295A patent/FI85218C/fi not_active IP Right Cessation
- 1984-06-07 GR GR74958A patent/GR82363B/el unknown
- 1984-06-07 NO NO842291A patent/NO168629C/no unknown
- 1984-06-07 ES ES533207A patent/ES8601697A1/es not_active Expired
- 1984-06-07 KR KR1019840003189A patent/KR910004572B1/ko not_active IP Right Cessation
- 1984-06-07 NZ NZ208416A patent/NZ208416A/en unknown
- 1984-06-07 DK DK280884A patent/DK162018C/da not_active IP Right Cessation
- 1984-06-07 JP JP59117431A patent/JPS6075435A/ja active Granted
- 1984-06-07 GB GB08414528A patent/GB2142235B/en not_active Expired
- 1984-06-07 HU HU842207A patent/HU192407B/hu not_active IP Right Cessation
- 1984-06-08 PT PT78711A patent/PT78711B/pt unknown
- 1984-06-08 AU AU29241/84A patent/AU562803B2/en not_active Ceased
-
1987
- 1987-05-30 SG SG48087A patent/SG48087G/en unknown
- 1987-07-06 MY MYPI87000950A patent/MY100764A/en unknown
- 1987-09-30 US US07/103,524 patent/US4873080A/en not_active Expired - Lifetime
- 1987-10-07 HK HK722/87A patent/HK72287A/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR850000241A (ko) | 경구용 당뇨병 치료제 제형의 제조방법 | |
| KR850000240A (ko) | 경구용 당뇨병 치료제 제형의 제조방법 | |
| FI872864A0 (fi) | Menetelmä farmaseuttisesti aktiivisten bentsimidatsolijohdannaisten valmistamiseksi | |
| PT84663A (en) | Process for the preparation of new pharmaceutical preparations with extended release comprising active compounds with very low solubility especially substituted dihydropyridines | |
| DE69008366T2 (de) | 2-Aminopyrimidinon-Derivate. | |
| ATE86616T1 (de) | Benzimidazolderivate mit einer wirkung als ulkusmittel. | |
| DE69606840D1 (de) | Monohydrate von Aminobenzensulfonsäurederivaten und Verfahren zu ihrer Herstellung | |
| DE69215965D1 (de) | Pyrazolopyridinverbindungen und Verfahren zu ihrer Herstellung | |
| NO940523D0 (no) | Nye pyrazin-derivater | |
| KR960034205A (ko) | 피페리딘 유도체와 그것의 제조방법 및 치료적 이용 | |
| KR910000158A (ko) | 의약용 화합물 및 그것의 사용방법 | |
| ATE55248T1 (de) | Arzneimittelkombination. | |
| ATE41772T1 (de) | Polymethoxybenzyl-piperazin-derivate, verfahren zu ihrer herstellung und diese derivate enthaltende pharmazeutische zusammensetzungen. | |
| KR950031075A (ko) | 새로운 3-페닐설포닐-3,7-디아자바이사이클로[3, 3, 1]노난-화합물을 함유하는 약제 | |
| SE8004383L (sv) | Farmaceutisk beredning for oral administrering och forfarande for dess framstellning | |
| ATE83482T1 (de) | Piperidin-derivate, deren herstellung und deren verwendung als heilmittel. | |
| ATE53209T1 (de) | Piperazinverbindungen, verfahren zu ihrer herstellung, pharmazeutische zusammensetzung und verwendung. | |
| KR880004810A (ko) | 소화성 궤양 치료제 | |
| TR200102087T2 (tr) | Yeni morfolinbenzamid tuzları | |
| ATE63114T1 (de) | Piperazinderivate, verfahren zu ihrer herstellung und diese als wirkstoffe enthaltende pharmazeutische zusammensetzungen. | |
| SE8603517L (sv) | Heterocykliska foreningar och deras framstellning och farmaceutiska formuleringar | |
| DE69200810D1 (de) | Benzoesäureethanolaminesterderivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen. | |
| ATE1606T1 (de) | Indanyloxaminsaeure-derivate, ihre herstellung und diese enthaltende pharmazeutische zusammensetzungen. | |
| TH6330EX (th) | กรรมวิธีสำหรับเตรียมอนุพันธ์ 1-แอลคิล ซัลสทิทิวเทดเบนซิมิดาโซลชนิดใหม่ | |
| TH5602EX (th) | สารประกอบทางเภสัชวิทยาชนิดใหม่ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| G160 | Decision to publish patent application | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20020621 Year of fee payment: 12 |
|
| LAPS | Lapse due to unpaid annual fee |